湖北亨迪药业股份有限公司(股票代码：301211.SZ) 2002年来开始承接CDMO业务，是中国领先的CDMO服务企业和特色原料药生产企业。20年来向全球跨国药企和新药研创公司提供委托研发和委托生产服务。能够为全球客户提供从新药临床前药学研究、临床及各阶段原料药工艺研发和生产、到商业化生产的一站式服务，其中包括多个中美双报项目。总反应能力约1000立方，涵盖多个OEB4-5高活性GMP生产线，反应釜体积5L~5000L，能承接从克、公斤、吨、百吨、千吨等不同规模的小分子原料药及中间体的合同研发与生产业务。

Hubei Heilen Pharmaceutical Co., Ltd. (stock code: 301211. SZ) has been undertaking CDMO business since 2002 and is a leading enterprise of CDMO service and generic API production in China. During past 20 years, we have provided CDMO/CMO services to global pharmaceutical companies and new drug research and development companies. We are able to provide one-stop services for global clients, including preclinical pharmaceutical research for new drugs, research and development and production of API at clinical and various stages, and commercial production, including multiple Sino US dual registration projects. The total reaction capacity is about 1000M3, covering multiple OEB4-5 Highly Potent API GMP production lines, with a reactor volume of 5L~5000L. It can undertake CDMO/CMO business of small molecule APIs and intermediates of different scales from grams/kilos to thousands of tons.